Christi Shaw
Known title: DirectorCIK: 0001702473
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Avantor to Report Q3 2026 Earnings on October 28. Avantor has scheduled its third-quarter 2026 earnings release for Wednesday, October 28, 2026. Recent coverage notes that the company led peer groups in research tools and consumables during the second quarter. The stock is currently trading near the lower end of its 52-week range, with analysts maintaining a wide target price spread.
Transaction History
| KYTX | ▼ Sell | Tax Withholding | 4,194 | $36K | 5/27/2026 | View on chart |
| KYTX | ▲ Buy | Grant | 24,301 | $0 | 1/12/2026 | View on chart |
| KYTX | ▲ Buy | Grant | 30,000 | $0 | 1/12/2026 | View on chart |
| KYTX | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 | View on chart |
| AVTR | ▲ Buy | Grant | 9,808 | $0 | 5/11/2023 | View on chart |
| AVTR | ▲ Buy | Grant | 6,693 | $0 | 5/12/2022 | View on chart |
| AVTR | ▲ Buy | Grant | 1,215 | $0 | 4/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials
Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.